Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad304 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Sofía Scévola und 12 weiteren Autor:innen. Beteiligte Einrichtung: HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of …. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Spanish Network for AIDS Research, Instituto de Salud Carlos III, Red Temática de Investigación Cooperativa en Sida.
Abstract (Originalsprache)
Background
Decay of HIV in seminal plasma (SP) and rectal fluid (RF) has not yet been described for the antiretroviral combination of dolutegravir (DTG) + lamivudine (3TC).
Methods
In this randomized multicenter pilot trial, males who were antiretroviral naive were randomized (2:1) to DTG + 3TC or bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). HIV-1 RNA was measured in blood plasma (BP), SP, and RF at baseline; days 3, 7, 14, and 28; and weeks 12 and 24.
Results
Of 25 individuals enrolled, 24 completed the study (DTG + 3TC, n = 16; BIC/FTC/TAF, n = 8). No significant differences were observed between groups for median decline in HIV-1 RNA from baseline at each time point or median time to achieve HIV-1 RNA <20 copies/mL in BP and SP and <20 copies/swab in RF. HIV-1 RNA decay patterns were compared in individuals receiving DTG + 3TC. Despite significantly higher percentages for changes from baseline in BP, median (IQR) times to HIV-1 RNA suppression were shorter in SP (7 days; 0–8.75) and RF (10.5 days; 3–17.5) than in BP (28 days; 14–84; P < .001).
Conclusions
Comparable HIV-1 RNA decay in BP, SP, and RF was observed between DTG + 3TC and BIC/FTC/TAF. As shown with triple-drug integrase inhibitor–based regimens, rapid HIV-1 RNA suppression in SP and RF is achieved with DTG + 3TC, despite decay patterns differing from those of BP. Clinical Trials Registration EudraCT 2019-004109-28.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
- Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
- HIV Unit, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
- Department of Internal Medicine, Sant Camil Hospital, Sant Pere de Ribes, Barcelona, Spain.
- Department of Infectious Diseases, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain.
- Department of Infectious Diseases, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain.
ORCID-Profile: Pere Domingo, Vicens Diaz-Brito, Arkaitz Imaz
Förderung
- Spanish Network for AIDS Research
- Instituto de Salud Carlos III
- Red Temática de Investigación Cooperativa en Sida
- ISCIII Subdirección General de Evaluación
- European Regional Development Fund
Zitieren
APA
Scévola, S., Niubó, J., Domingo, P., Verdejo, G., Curran, A., Diaz-Brito, V., Peñafiel, J., Tiraboschi, J., Morenilla, S., Garcia, B., Soriano, I., Podzamczer, D., & Imaz, A. (2023). Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad304
Vancouver
Scévola S, Niubó J, Domingo P, Verdejo G, Curran A, Diaz-Brito V, et al. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad304
BibTeX
@article{Scvola2023,
author = {Scévola, Sofía and Niubó, Jordi and Domingo, Pere and Verdejo, Guillermo and Curran, Adrian and Diaz-Brito, Vicens and Peñafiel, Judith and Tiraboschi, Juan and Morenilla, Sandra and Garcia, Benito and Soriano, Irene and Podzamczer, Daniel and Imaz, Arkaitz},
title = {Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad304}
}
EUVIMED